Novartis drug inclisiran wasn’t reviewed on time by the FDA—largely because of COVID-19 travel restrictions. Now, the company seeks to price the drug when it hits the market. A recent review by the Institute for Clinical and Economic Review (ICER) provides insight on pricing. The ultimate fate of the Novartis drug—and its price—are still unknown.
According to Victor Bulto, president of US Pharmaceuticals for Novartis, “We will price at a level that allows us to have a broader impact on society and allows us to minimize non-clinical barriers.” Read more here.
(Source: Ned Pagliarulo, BioPharmaDive, 1/22/21)